Biotech company Alizyme suffered another blow yesterday as its share price halved after disappointing trial results.

Its shares fell 49.9 per cent to a record low of 7.76p after the results of late-stage clinical trials showed its treatment for inflamed bowels was not as effective as the standard therapy.